| Authors: |
Powell PA; Sheffield Centre of Health and Related Research (SCHARR), University of Sheffield, Sheffield, UK., Frances SM; Sheffield Centre of Health and Related Research (SCHARR), University of Sheffield, Sheffield, UK., de Galan BE; Department of Medicine, Radboud University Medical Centre, Nijmegen, GA, The Netherlands.; Department of Internal Medicine, Maastricht University Medical Center+, Maastricht, ER, The Netherlands.; CARIM Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, ER, The Netherlands., Heller S; Department of Oncology and Human Metabolism, University of Sheffield, Sheffield, UK., Speight J; School of Psychology|Institute for Health Transformation, Deakin University, Geelong, Victoria, Australia.; The Australian Centre for Behavioural Research in Diabetes, Diabetes Victoria, Carlton, Victoria, Australia., Rosilio M; Diabetes & Obesity Medical Unit, Eli Lilly & Company, Neuilly sur seine, France., Pouwer F; Department of Psychology, University of Southern Denmark, Odense, Denmark.; Steno Diabetes Center Odense, Odense, Denmark.; Department of Health and Caring Sciences, Western Norway University of Applied Sciences, Bergen, Norway., Gall MA; Novo Nordisk A/S, Medical & Science, Diabetes, Clinical Development & Project Leadership, Søborg, Denmark., Child CJ; Eli Lilly and Company, Cardiometabolic Health, Bracknell, UK., McCrimmon RJ; School of Medicine, University of Dundee, Dundee, Scotland, UK., Tait K; Diabetes Advocate, London, UK., Carlton J; Sheffield Centre of Health and Related Research (SCHARR), University of Sheffield, Sheffield, UK. |
